Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.

Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA, Lund EA, Sam TN, Kersey JH.

Cancer Cell. 2008 May;13(5):432-40. doi: 10.1016/j.ccr.2008.03.005.

2.

MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.

Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA.

Leukemia. 2008 Jan;22(1):66-77. Epub 2007 Sep 13.

3.

EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.

Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR.

Blood. 2012 Jun 14;119(24):5838-49. doi: 10.1182/blood-2011-11-393827. Epub 2012 May 2.

4.

The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.

Osaki H, Walf-Vorderwülbecke V, Mangolini M, Zhao L, Horton SJ, Morrone G, Schuringa JJ, de Boer J, Williams O.

Leukemia. 2013 Jul;27(7):1461-8. doi: 10.1038/leu.2013.42. Epub 2013 Feb 13.

PMID:
23403462
5.

MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny.

Horton SJ, Jaques J, Woolthuis C, van Dijk J, Mesuraca M, Huls G, Morrone G, Vellenga E, Schuringa JJ.

Leukemia. 2013 Apr;27(5):1116-26. doi: 10.1038/leu.2012.343. Epub 2012 Nov 26.

PMID:
23178754
6.

An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model.

Bergerson RJ, Collier LS, Sarver AL, Been RA, Lugthart S, Diers MD, Zuber J, Rappaport AR, Nixon MJ, Silverstein KA, Fan D, Lamblin AF, Wolff L, Kersey JH, Delwel R, Lowe SW, O'Sullivan MG, Kogan SC, Adams DJ, Largaespada DA.

Blood. 2012 May 10;119(19):4512-23. doi: 10.1182/blood-2010-04-281428. Epub 2012 Mar 16.

7.

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA.

Nature. 2006 Aug 17;442(7104):818-22. Epub 2006 Jul 16.

PMID:
16862118
8.

IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.

Jenkins CR, Shevchuk OO, Giambra V, Lam SH, Carboni JM, Gottardis MM, Holzenberger M, Pollak M, Humphries RK, Weng AP.

Exp Hematol. 2012 Sep;40(9):715-723.e6. doi: 10.1016/j.exphem.2012.05.003. Epub 2012 May 18.

PMID:
22613471
9.

Plzf drives MLL-fusion-mediated leukemogenesis specifically in long-term hematopoietic stem cells.

Ono R, Masuya M, Nakajima H, Enomoto Y, Miyata E, Nakamura A, Ishii S, Suzuki K, Shibata-Minoshima F, Katayama N, Kitamura T, Nosaka T.

Blood. 2013 Aug 15;122(7):1271-83. doi: 10.1182/blood-2012-09-456665. Epub 2013 Jul 9.

10.

Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia.

Johnson JJ, Chen W, Hudson W, Yao Q, Taylor M, Rabbitts TH, Kersey JH.

Blood. 2003 Apr 15;101(8):3229-35. Epub 2002 Dec 19.

11.

CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis.

Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I, Hess JL.

Cancer Cell. 2011 Nov 15;20(5):563-75. doi: 10.1016/j.ccr.2011.09.008.

12.

Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.

Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JS, Zheng Y, Cancelas JA, Gu Y, Jansen M, Dimartino JF, Mulloy JC.

Cancer Cell. 2008 Jun;13(6):483-95. doi: 10.1016/j.ccr.2008.04.020.

13.

MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

Monroe SC, Jo SY, Sanders DS, Basrur V, Elenitoba-Johnson KS, Slany RK, Hess JL.

Exp Hematol. 2011 Jan;39(1):77-86.e1-5. doi: 10.1016/j.exphem.2010.09.003. Epub 2010 Sep 18.

14.

MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.

Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, Zhang H, Liu Z, Ernst P, Koretzky GA, Hua X.

Cancer Cell. 2010 Feb 17;17(2):148-59. doi: 10.1016/j.ccr.2009.12.034.

15.

The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.

Thiel AT, Feng Z, Pant DK, Chodosh LA, Hua X.

Haematologica. 2013 Jun;98(6):918-27. doi: 10.3324/haematol.2012.074195. Epub 2013 Jan 24.

16.

MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.

Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, Tzankov A, Iacovino M, Lau IJ, Milne TA, Royo H, Kyba M, Valk PJ, Peters AH, Schwaller J.

Cancer Cell. 2016 Jul 11;30(1):43-58. doi: 10.1016/j.ccell.2016.05.011. Epub 2016 Jun 23.

PMID:
27344946
17.

MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?

Muntean AG, Hess JL.

Cancer Cell. 2008 Jun;13(6):465-7. doi: 10.1016/j.ccr.2008.05.012.

18.
19.

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.

Nguyen AT, Taranova O, He J, Zhang Y.

Blood. 2011 Jun 23;117(25):6912-22. doi: 10.1182/blood-2011-02-334359. Epub 2011 Apr 26.

Supplemental Content

Support Center